Speakers
Session
Companies deploying biosolutions have the potential to change the world across multiple sectors. A harmonised, transparent and accessible regulatory environment is necessary not only to ensure responsible innovation of these disruptive biotechnologies, but also to protect UK biosolutions companies from uncertainty in their development pipelines, investor nervousness and global market volatility.
In this session we will explore how the UK can foster a globally attractive culture of responsible BioSolutions innovation – enabling companies to innovate rapidly and at scale, while reducing biosecurity risks, maintaining public trust, and supporting a stable operating environment attractive to investors.
Jeffrey Anthony joined NPL in 2019 and works as part of NPL’s Life Sciences & Health Partnerships Team. With a focus on the building collaborations across the Life science sector Jeffrey works with collaborators across industry, academic and public sector to identify the ways in which NPL’s metrology expertise and capability can help to support research and its translation to drive growth.
Jeffrey’s technical background is in microbiology, and he has worked in roles across quality assurance, and both product and business development. His experience includes the pharmaceutical sector, the development of genomic marker technologies in agritech and activities in cell biology. In his current role his time is dedicated to building partnerships across the UK and internationally across standards and metrology in Engineering Biology supporting companies in their quest to scale and commercialise at pace.